抗血管生成治疗的现状及挑战被引量：1

Antiangiogenic Therapy and Tumor Microenvironment

在线阅读下载PDF

导出

摘要肿瘤的形成是一个复杂的动态过程,由发生、发展和转移三个阶段组成。肿瘤微环境是一个复杂的局部病理环境,可诱导新生血管生成。而血管生成是促进肿瘤各阶段发生的重要条件,因此,抗血管生成已成为目前肿瘤治疗的新策略。大量研究表明,抗血管生成治疗在多种肿瘤中均显示出临床获益,如非小细胞肺癌、软骨肉瘤等。除此之外,抗血管生成治疗联合PD-1/PD-L1单抗免疫治疗也是目前的研究热点之一,有研究表明两种治疗方法联合可以增强治疗效果。然而,近年来在临床实践中发现,抗血管生成药物的耐药性、缺乏有效的预测性生物标志物等问题仍无法规避,疗效也不够理想,甚至有些短期治疗可能增加肿瘤的侵袭性,发生上述现象的原因与肿瘤微环境的反应性改变密切相关。本文就抗血管生成治疗与肿瘤微环境的研究进展及目前面临的挑战作一简要综述。 Tumor formation is a complex and dynamic process consisting of three phases:occurrence,development and metastasis.The tumor microenvironment is a complex local pathological environment that can induce neovascularization,and angiogenesis is an important condition for tumorigenesis,development and metastasis.Thus,antiangiogenic therapy becomes a new target for tumor therapy.Numerous studies have shown that clinical benefits have been achieved from antiangiogenic therapy for many tumors,such as non-small cell lung cancer,chondrosarcoma and the like.In addition,antiangiogenic therapy combined with PD-1/PD-L1 monoclonal antibody immunotherapy is also one of the current research hotspots.Some studies have shown that the combination of the two treatment strategies can enhance the efficacy.However,in recent years,it has been found in clinical practice that anti-angiogenesis drugs resistance,lack of predictive biomarkers and other problems are still unavoidable.Yet the curative effect is not entirely satisfactory.Even some of short-term treatments might increase the invasiveness of tumors.The reasons for the above phenomena are closely related to the changes in the responsiveness of tumor microenvironment.This article provides a brief review of the current challenges of tumor microenvironment-mediated anti-angiogenic therapy to improve the clinical efficacy of anti-tumor angiogenesis therapy.

作者葛菁茹王伟何义富 GE Jingru;WANG Wei;HE Yifu(Department of Medical Oncology,Anhui Provincial Hospital Affiliated to Anhui Medical University,Hefei,Anhui,230001,China;Department of Medical Oncology,the First Affiliated Hospital of University of Science and Technology of China/Anhui Provincial Hospital,Hefei,Anhui,230001,China)

机构地区安徽医科大学附属省立医院肿瘤内科中国科学技术大学附属第一医院/安徽省立医院肿瘤内科

出处《肿瘤药学》 CAS 2019年第6期845-849,864,共6页 Anti-Tumor Pharmacy

基金安徽省自然科学基金(1808085MH234、1708085QH177) 中国肝炎防治基金会——天晴肝病研究基金资助课题(TQGB20170171)

关键词抗血管生成治疗肿瘤微环境 Antiangiogenic therapy Tumor microenvironment

分类号 R730.5 [医药卫生—肿瘤]

作者简介葛菁茹,女,硕士研究生,研究方向:消化道肿瘤,E-mail:GJR9678@163.com;通讯作者:何义富,男,博士,主任医师,研究方向:消化道肿瘤,Email:yifuhe@fsyy.ustc.edu.cn。